[go: up one dir, main page]

WO2006078941A3 - Novel sirtuin activating compounds and methods of use thereof - Google Patents

Novel sirtuin activating compounds and methods of use thereof Download PDF

Info

Publication number
WO2006078941A3
WO2006078941A3 PCT/US2006/002092 US2006002092W WO2006078941A3 WO 2006078941 A3 WO2006078941 A3 WO 2006078941A3 US 2006002092 W US2006002092 W US 2006002092W WO 2006078941 A3 WO2006078941 A3 WO 2006078941A3
Authority
WO
WIPO (PCT)
Prior art keywords
activating compounds
methods
sirtuin
diseases
sirtuin activating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/002092
Other languages
French (fr)
Other versions
WO2006078941A2 (en
Inventor
Michael Milburn
Jens W Eckstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirtris Pharmaceuticals Inc
Original Assignee
Sirtris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirtris Pharmaceuticals Inc filed Critical Sirtris Pharmaceuticals Inc
Publication of WO2006078941A2 publication Critical patent/WO2006078941A2/en
Publication of WO2006078941A3 publication Critical patent/WO2006078941A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided herein are novel sirtuin-activating compounds and methods of use thereof. The sirtuin-activating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing. Also provided are compositions comprising a sirtuin-activating compound in combination with another therapeutic agent.
PCT/US2006/002092 2005-01-20 2006-01-20 Novel sirtuin activating compounds and methods of use thereof Ceased WO2006078941A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64591605P 2005-01-20 2005-01-20
US60/645,916 2005-01-20

Publications (2)

Publication Number Publication Date
WO2006078941A2 WO2006078941A2 (en) 2006-07-27
WO2006078941A3 true WO2006078941A3 (en) 2007-02-22

Family

ID=36603673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/002092 Ceased WO2006078941A2 (en) 2005-01-20 2006-01-20 Novel sirtuin activating compounds and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2006078941A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9162083B2 (en) 2007-07-31 2015-10-20 Elc Management Llc Linoleic and Linolenic acid esters of resveratrol and cosmetic compositions
US9220669B2 (en) 2007-09-08 2015-12-29 Elc Management Llc Resveratrol ferulate compounds, compositions containing the compounds, and methods of using the same

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302573D0 (en) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US20050171027A1 (en) 2003-12-29 2005-08-04 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
DE602004026647D1 (en) 2004-09-14 2010-05-27 Ajinomoto Omnichem S A TOPICAL COMPOSITIONS WITH PHOSPHORYLATED POLYPHENOLES
BRPI0515897A (en) 2004-09-24 2008-08-12 Astrazeneca Ab compound, use thereof, pharmaceutical composition, and method for pain therapy in a warm-blooded animal, and for the preparation of a compound
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
AU2008240103A1 (en) * 2007-04-12 2008-10-23 Massachusetts Institute Of Technology Sirtuin based methods and compositions for treating beta- catenin-related conditions
US9295621B2 (en) 2007-07-31 2016-03-29 Elc Management Llc Emulsion cosmetic compositions containing resveratrol derivatives and silicone surfactant
US8344024B2 (en) 2007-07-31 2013-01-01 Elc Management Llc Anhydrous cosmetic compositions containing resveratrol derivatives
US20090035236A1 (en) 2007-07-31 2009-02-05 Maes Daniel H Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And An Oil Phase Structuring Agent
EP2247299A4 (en) * 2007-12-21 2012-06-06 Univ Rochester MOLECULAR TARGETS FOR THE TREATMENT OF INFLAMMATION
EP2367563A4 (en) 2008-12-08 2012-12-19 Univ Northwestern METHOD FOR MODULATING HSF-1
US8916528B2 (en) 2011-11-16 2014-12-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
US9650637B2 (en) 2012-01-24 2017-05-16 Bar-Ilan University Treatment of disease by modulation of SIRT6
WO2013111081A1 (en) 2012-01-24 2013-08-01 Bar-Ilan University Treatment of disease by modulation of sirt6
SG11201600241RA (en) 2013-07-18 2016-02-26 Novartis Ag Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
ES2968371T3 (en) 2013-10-10 2024-05-09 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as 12-lipoxygenase inhibitors
MX2021012250A (en) 2019-04-11 2022-01-18 Angion Biomedica Corp Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole.
CN114957171B (en) * 2022-06-21 2024-07-30 广东工业大学 A novel five-membered heterocyclic substituted styrene derivative and its preparation method and application

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1356221A (en) * 1971-08-04 1974-06-12 Pfizer 1- 3-hydroxystyryl- pyridinium salts and their derivatives as whipworm control agents
EP0334119A1 (en) * 1988-03-21 1989-09-27 Boehringer Ingelheim Pharmaceuticals Inc. Compounds for inhibiting the biosynthesis of lipoxygenase-derived metabolites of arachidonic acid
EP0499415A1 (en) * 1991-02-11 1992-08-19 Zeneca Limited Pyridine and quinoline derivatives, processes for their manufacture and their use as angiotensin II antagonists
US5399575A (en) * 1990-12-01 1995-03-21 Boehringer Mannheim Gmbh Pyridine compounds which have useful pharmaceutical activity
EP0754682A1 (en) * 1994-04-06 1997-01-22 Nippon Shinyaku Company, Limited Aminostilbazole derivative and medicine
PL172112B1 (en) * 1993-08-09 1997-08-29 Univ Adama Mickiewicza (E) -N-dodecyl- / or bromodecyl- / 2- / 3- or 4- / hydroxy-a-stilbazolium bromides and the method of obtaining new (E) -N-dodecyl- / or bromodecyl- / 2- / 3 bromides - or 4- (hydroxy-α-stilbazolium)
JP2001261649A (en) * 2000-03-15 2001-09-26 Sankyo Co Ltd Sulfonamide derivative
US6355443B1 (en) * 1999-03-17 2002-03-12 Mark Norman Bobrow 4-(4-hydroxystyryl) pyridine-containing substrates for an analyte dependent enzyme activation system
WO2002057219A1 (en) * 2001-01-18 2002-07-25 Welichem Biotech Inc. Novel 1,2-diphenylethene derivatives for treatment of immune diseases
US20020177637A1 (en) * 2001-03-13 2002-11-28 The Ohio State University Polymers and oligomers, their synthesis, and electronic devices incorporating same
WO2004022665A1 (en) * 2002-09-09 2004-03-18 National Institute Of Advanced Industrial Science And Technology Two-photon absorption materials

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1356221A (en) * 1971-08-04 1974-06-12 Pfizer 1- 3-hydroxystyryl- pyridinium salts and their derivatives as whipworm control agents
EP0334119A1 (en) * 1988-03-21 1989-09-27 Boehringer Ingelheim Pharmaceuticals Inc. Compounds for inhibiting the biosynthesis of lipoxygenase-derived metabolites of arachidonic acid
US5399575A (en) * 1990-12-01 1995-03-21 Boehringer Mannheim Gmbh Pyridine compounds which have useful pharmaceutical activity
EP0499415A1 (en) * 1991-02-11 1992-08-19 Zeneca Limited Pyridine and quinoline derivatives, processes for their manufacture and their use as angiotensin II antagonists
PL172112B1 (en) * 1993-08-09 1997-08-29 Univ Adama Mickiewicza (E) -N-dodecyl- / or bromodecyl- / 2- / 3- or 4- / hydroxy-a-stilbazolium bromides and the method of obtaining new (E) -N-dodecyl- / or bromodecyl- / 2- / 3 bromides - or 4- (hydroxy-α-stilbazolium)
EP0754682A1 (en) * 1994-04-06 1997-01-22 Nippon Shinyaku Company, Limited Aminostilbazole derivative and medicine
US6355443B1 (en) * 1999-03-17 2002-03-12 Mark Norman Bobrow 4-(4-hydroxystyryl) pyridine-containing substrates for an analyte dependent enzyme activation system
JP2001261649A (en) * 2000-03-15 2001-09-26 Sankyo Co Ltd Sulfonamide derivative
WO2002057219A1 (en) * 2001-01-18 2002-07-25 Welichem Biotech Inc. Novel 1,2-diphenylethene derivatives for treatment of immune diseases
US20020177637A1 (en) * 2001-03-13 2002-11-28 The Ohio State University Polymers and oligomers, their synthesis, and electronic devices incorporating same
WO2004022665A1 (en) * 2002-09-09 2004-03-18 National Institute Of Advanced Industrial Science And Technology Two-photon absorption materials

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HAROUTOUNIAN S A ET AL: "4'-Hydroxystyryldiazines: Synthesis and Fluorescence Properties", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 51, no. 6, February 1995 (1995-02-01), pages 1585 - 1598, XP004104849, ISSN: 0040-4020 *
HOWITZ K T ET AL: "SMALL MOLECULE ACTIVATORS OF SIRTUINS EXTEND SACCHAROMYCES CEREVISIAE LIFESPAN", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 425, 11 September 2003 (2003-09-11), pages 191 - 196, XP001188967, ISSN: 0028-0836 *
LAZER E S ET AL: "ANTIINFLAMMATORY 2,6-DI-TERT-BUTYL-4-(2-ARYLETHENYL)PHENOLS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 32, no. 1, 1989, pages 100 - 104, XP000973857, ISSN: 0022-2623 *
PAPA D; ET AL: "X-Ray Diagnostics. VI.", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 73, 1951, pages 253 - 255, XP002388920 *
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 26 1 July 2002 (2002-07-01) *
PORCU M ET AL: "The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, vol. 26, no. 2, February 2005 (2005-02-01), pages 94 - 103, XP004727629, ISSN: 0165-6147 *
QUIDEAU S: "PLANT POLYPHENOLIC SMALL MOLECULES CAN INDUCE A CALORIE RESTRICTION-MIMETIC LIFE-SPAN EXTENSION BY ACTIVATING SIRTUINS: WILL POLYPHENOLS SOMEDAY BE USED AS CHEMOTHERAPEUTIC DRUGS IN WESTERN MEDICINE?", CHEMBIOCHEM - A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY, WILEY VCH, WEINHEIM, DE, vol. 5, no. 4, 2 April 2004 (2004-04-02), pages 427 - 430, XP009057585, ISSN: 1439-4227 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9162083B2 (en) 2007-07-31 2015-10-20 Elc Management Llc Linoleic and Linolenic acid esters of resveratrol and cosmetic compositions
US9220669B2 (en) 2007-09-08 2015-12-29 Elc Management Llc Resveratrol ferulate compounds, compositions containing the compounds, and methods of using the same

Also Published As

Publication number Publication date
WO2006078941A2 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
WO2006105440A3 (en) Nicotinamide riboside and analogues thereof
WO2006078941A3 (en) Novel sirtuin activating compounds and methods of use thereof
WO2007019344A8 (en) Imidazo [2,1-b] thiazole derivatives as sirtuin modulating compounds
WO2008156869A3 (en) Sirtuin modulating thiazolopyridine compounds
WO2006094209A3 (en) N-benzimidazolylalkyl-substituted amide sirtuin modulators
MY149316A (en) Sirtuin modulating imidazohiazole compounds
WO2010037127A8 (en) Chromenone analogs as sirtuin modulators
WO2009134973A8 (en) Quinolines and related analogs as sirtuin modulators
WO2006094237A3 (en) Acridine and quinoline dervatives as sirtuin modulators
WO2009061453A8 (en) Solubilized thiazolopyridines
MY160006A (en) Thiazolopyridine sirtuin modulating compounds
IN2012DN03799A (en)
WO2008100376A3 (en) Truncation variants of sirt1 and methods of use thereof
MX2010004965A (en) Amide derivatives as sirtuin modulators.
WO2007102861A3 (en) Modulators of cdc2-like kinases (clks) and methods of use thereof
MX2011006084A (en) Isoindolinone and related analogs as sirtuin modulators.
MX2010012961A (en) Imidazopyridine and related analogs as sirtuin modulators.
MX2011006475A (en) Phthalazinone and related analogs as sirtuin modulators.
WO2009085226A3 (en) Inhibitors of cdc2-like kinases (clks) and methods of use thereof
WO2006094210A3 (en) Tetrahydroquinoxalinone sirtuin modulators
LTC1620113I2 (en) Ivermectin topical composition for the treatment of dermatological diseases
WO2007127474A3 (en) Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2007104789A3 (en) Amylin derivatives
WO2007130383A3 (en) Compositions and treatments using pyridazine compounds and secretases
WO2009042922A3 (en) Peptide-peptidase inhibitor conjugates and methods of making and using same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06719063

Country of ref document: EP

Kind code of ref document: A2